Patents by Inventor Norio Hamamatsu

Norio Hamamatsu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190135908
    Abstract: Provided herein are monoclonal antibodies (e.g., human antibodies) binding to human Growth Differentiation Factor 15 protein (hereinafter, sometimes referred to as “GDF15”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Application
    Filed: April 26, 2017
    Publication date: May 9, 2019
    Inventors: Hong CHEN, Rajiv CHOPRA, Seung Wan HAHM, Norio HAMAMATSU, Ryan Scott STREEPER, Mei XU
  • Publication number: 20180369332
    Abstract: The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.
    Type: Application
    Filed: August 30, 2018
    Publication date: December 27, 2018
    Inventors: Brian R. Boettcher, Shari Lynn Caplan, Douglas S. Daniels, Norio Hamamatsu, Stuart Licht, Stephen Craig Weldon
  • Patent number: 10076554
    Abstract: The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.
    Type: Grant
    Filed: January 4, 2016
    Date of Patent: September 18, 2018
    Assignee: Novartis AG
    Inventors: Brian R. Boettcher, Shari Lynn Caplan, Douglas S. Daniels, Norio Hamamatsu, Stuart Licht, Stephen Craig Weldon
  • Publication number: 20170204149
    Abstract: The disclosure relates to fusion polypeptides comprising serum albumin or a functional variant thereof and GDF15 protein or a functional variant thereof and to pharmaceutical compositions that contain the fusion polypeptides, nucleic acids that encode the fusion polypeptides, methods of making the polypeptides and use of the polypeptides to decreasing appetite, decreasing body weight and treating metabolic diseases.
    Type: Application
    Filed: June 19, 2015
    Publication date: July 20, 2017
    Applicant: NOVARTIS AG
    Inventors: Rajiv CHOPRA, Norio HAMAMATSU, Ryan Scott STREEPER, Brian Edward VASH
  • Publication number: 20170166621
    Abstract: The present invention relates to the identification of new proteins comprising fibroblast growth factor 21 (FGF21) and other metabolic regulators, including variants thereof, known to improve metabolic profiles in subjects to whom they are administered. Also disclosed are methods for treating FGF21-associated disorders, GLP-1-associated disorders, and Exendin-4-associated disorders, including metabolic conditions.
    Type: Application
    Filed: August 26, 2016
    Publication date: June 15, 2017
    Applicant: NOVARTIS AG
    Inventors: Brian R. BOETTCHER, Shari Lynn CAPLAN, Susan E. CELLITTI, Douglas S. DANIELS, Norio HAMAMATSU, Bernhard Hubert GEIERSTANGER, Stuart LICHT, Andreas LOEW, Stephen Craig WELDON
  • Patent number: 9458214
    Abstract: The present invention relates to dual function fusions proteins comprising fibroblast growth factor 21 (FGF21) and Exenatide, Exendin-4, or GLP-1. Also disclosed are methods for treating FGF21-associated disorders, GLP-1-associated disorders, and Exendin-4-associated disorders, including metabolic conditions.
    Type: Grant
    Filed: September 25, 2012
    Date of Patent: October 4, 2016
    Assignee: NOVARTIS AG
    Inventors: Brian R. Boettcher, Shari L. Caplan, Douglas S. Daniels, Norio Hamamatsu, Stuart Licht, Stephen Craig Weldon, Susan E. Cellitti, Bernhard Hubert Geierstranger, Andreas Loew
  • Publication number: 20160193297
    Abstract: The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.
    Type: Application
    Filed: January 4, 2016
    Publication date: July 7, 2016
    Applicant: NOVARTIS AG
    Inventors: BRIAN R. BOELTCHER, SHARI LYNN CAPLAN, DOUGLAS S. DANIELS, NORIO HAMAMATSU, STUART LICHT, STEPHEN CRAIG WELDON
  • Publication number: 20160051628
    Abstract: The invention relates to the identification of new polypeptide and protein variants of fibroblast growth factor 21 (FGF21) that have improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.
    Type: Application
    Filed: April 2, 2015
    Publication date: February 25, 2016
    Applicants: IRM LLC, NOVARTIS AG
    Inventors: Brian R. BOETTCHER, Andreas LOEW, Shari L. CAPLAN, Douglas S. DANIELS, Bernhard H. GEIERSTANGER, Norio HAMAMATSU, Stuart LICHT, Stephen Craig WELDON
  • Patent number: 9266935
    Abstract: The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.
    Type: Grant
    Filed: February 24, 2015
    Date of Patent: February 23, 2016
    Assignee: Novartis AG
    Inventors: Brian R. Boettcher, Shari L. Caplan, Douglas S. Daniels, Norio Hamamatsu, Stuart Licht, Stephen Craig Weldon
  • Publication number: 20150166622
    Abstract: The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.
    Type: Application
    Filed: February 24, 2015
    Publication date: June 18, 2015
    Inventors: Brian R. Boettcher, Shari L. Caplan, Douglas S. Daniels, Norio Hamamatsu, Stuart Licht, Stephen Craig Weldon
  • Patent number: 9023791
    Abstract: The present invention provides novel polypeptide and protein variants of fibroblast growth factor 21 (FGF21) and pharmaceutical compositions comprising FGF21 polypeptide and protein variants.
    Type: Grant
    Filed: November 15, 2011
    Date of Patent: May 5, 2015
    Assignees: Novartis AG, IRM LLC
    Inventors: Brian R. Boettcher, Shari L. Caplan, Douglas S. Daniels, Bernhard H. Geierstanger, Norio Hamamatsu, Stuart Licht, Andreas Loew, Stephen Craig Weldon
  • Patent number: 9006400
    Abstract: The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.
    Type: Grant
    Filed: September 25, 2012
    Date of Patent: April 14, 2015
    Assignee: Novartis AG
    Inventors: Brian R. Boettcher, Shari L. Caplan, Douglas S. Daniels, Norio Hamamatsu, Stuart Licht, Stephen Craig Weldon
  • Publication number: 20130079500
    Abstract: The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.
    Type: Application
    Filed: September 25, 2012
    Publication date: March 28, 2013
    Inventors: Brian R. Boettcher, Shari L. Caplan, Douglas S. Daniels, Norio Hamamatsu, Stuart Licht, Stephen Craig Weldon
  • Publication number: 20120129766
    Abstract: The invention relates to the identification of new polypeptide and protein variants of fibroblast growth factor 21 (FGF21) that have improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.
    Type: Application
    Filed: November 15, 2011
    Publication date: May 24, 2012
    Applicants: IRM LLC, NOVARTIS AG
    Inventors: Brian R. BOETTCHER, Shari L. CAPLAN, Douglas S. DANIELS, Bernhard H. GEIERSTANGER, Norio HAMAMATSU, Stuart LICHT, Andreas LOEW, Stephen Craig WELDON
  • Patent number: 7534443
    Abstract: An oil-in-water emulsion that comprise a bacterial component as an active ingredient as well as essentially an oil, surfactant, and a stabilizer, and that can be used as an agent for immunotherapy, and the preparation therefor are provided.
    Type: Grant
    Filed: July 16, 1999
    Date of Patent: May 19, 2009
    Assignees: Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Ichiro Azuma, Norio Hamamatsu, Toshio Fujinaga
  • Publication number: 20080152738
    Abstract: An oil-in-water emulsion that comprise a bacterial component as an active ingredient as well as essentially an oil, surfactant, and a stabilizer, and that can be used as an agent for immunotherapy, and the preparation therefor are provided.
    Type: Application
    Filed: October 4, 2007
    Publication date: June 26, 2008
    Applicants: Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Ichiro AZUMA, Norio Hamamatsu, Toshio Fujinaga
  • Patent number: 7037698
    Abstract: A modified pyrroloquinoline quinone-dependent glucose dehydrogenase having a low reactivity with respect to maltose, galactose, etc. is provided. A modified pyrroloquinoline quinone-dependent glucose dehydrogenase including an amino acid sequence in which one or more amino acids in a region corresponding to a first region consisting of amino acids at positions 326 to 354 in pyrroloquinoline quinone-dependent glucose dehydrogenase derived from Acinetobacter calcoaceticus are substituted as compared with an amino acid sequence of the corresponding wild-type enzyme.
    Type: Grant
    Filed: May 19, 2004
    Date of Patent: May 2, 2006
    Assignee: Amano Enzyme Inc.
    Inventors: Akitoshi Suzumura, Norio Hamamatsu
  • Publication number: 20050260728
    Abstract: A modified pyrroloquinoline quinone-dependent glucose dehydrogenase having a low reactivity with respect to maltose, galactose, etc. is provided. A modified pyrroloquinoline quinone-dependent glucose dehydrogenase including an amino acid sequence in which one or more amino acids in a region corresponding to a first region consisting of amino acids at positions 326 to 354 in pyrroloquinoline quinone-dependent glucose dehydrogenase derived from Acinetobacter calcoaceticus are substituted as compared with an amino acid sequence of the corresponding wild- type enzyme.
    Type: Application
    Filed: May 19, 2004
    Publication date: November 24, 2005
    Applicant: AMANO ENZYME INC.
    Inventors: Akitoshi Suzumura, Norio Hamamatsu